Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis an economic evaluation

Michael S. Schechter, David Trueman, Rachel Farquharson, Keiko Higuchi, Cori L Daines

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Rationale: Pseudomonas aeruginosa infection is a significant cause of morbidity and mortality in patients with cystic fibrosis and is associated with a high economic burden. A recently published comparator trial demonstrated that outcomes in patients with cystic fibrosis with chronic P. aeruginosa infections switched from tobramycin solution for inhalation to aztreonam lysine for inhalation were better than those of patients who continued on tobramycin. Objectives: To compare overall costs of treatment of chronic inhaled tobramycin and aztreonam lysine in patient with cystic fibrosis who have chronic Pseudomonas infection, taking differences in outcomes into account. Methods: A cost-effectiveness analysis with a 3-year time horizon was performed to simulate the economic consequences of either treatment from the perspective of a third party payer in the United States. We extrapolated results from the comparator trial and used data regarding clinical outcomes, quality of life, and costs from published literature and proprietary databases. A Markov structure was used to consider transitions between health states, defined principally by levels of percent predicted of FEV<inf>1</inf>. Extensive scenario and probabilistic sensitivity analyses were performed. Measurements and Main Results: Use of aztreonam lysine for inhalation was associated with an average cost saving of $41,947 per patient over 3 years, as well as greater quality-adjusted life-years and total life-years. Scenario analyses demonstrated that these findings were robust to changes in key assumptions. Conclusions: It appears, with high likelihood, that the use of aztreonam solution for inhalation is associated with cost savings, an increase in quality-adjusted life-years, and improved clinical outcomes among patients with extensive prior use of tobramycin solution for inhalation who are naive to inhaled aztreonam lysine.

Original languageEnglish (US)
Pages (from-to)1030-1038
Number of pages9
JournalAnnals of the American Thoracic Society
Volume12
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Aztreonam
Tobramycin
Cystic Fibrosis
Lysine
Cost-Benefit Analysis
Inhalation
Pseudomonas Infections
Quality-Adjusted Life Years
Pseudomonas aeruginosa
Health Transition
Economics
Health Insurance Reimbursement
Costs and Cost Analysis
Cost Savings
Health Care Costs
Quality of Life
Databases
Morbidity
Mortality

Keywords

  • Aztreonam lysine for inhalation
  • Cost analysis
  • Cystic fibrosis
  • Economic evaluation
  • Tobramycin solution for inhalation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis an economic evaluation. / Schechter, Michael S.; Trueman, David; Farquharson, Rachel; Higuchi, Keiko; Daines, Cori L.

In: Annals of the American Thoracic Society, Vol. 12, No. 7, 01.07.2015, p. 1030-1038.

Research output: Contribution to journalArticle

Schechter, Michael S. ; Trueman, David ; Farquharson, Rachel ; Higuchi, Keiko ; Daines, Cori L. / Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis an economic evaluation. In: Annals of the American Thoracic Society. 2015 ; Vol. 12, No. 7. pp. 1030-1038.
@article{748d1b5eba8a4969b1bf4c85715536d5,
title = "Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis an economic evaluation",
abstract = "Rationale: Pseudomonas aeruginosa infection is a significant cause of morbidity and mortality in patients with cystic fibrosis and is associated with a high economic burden. A recently published comparator trial demonstrated that outcomes in patients with cystic fibrosis with chronic P. aeruginosa infections switched from tobramycin solution for inhalation to aztreonam lysine for inhalation were better than those of patients who continued on tobramycin. Objectives: To compare overall costs of treatment of chronic inhaled tobramycin and aztreonam lysine in patient with cystic fibrosis who have chronic Pseudomonas infection, taking differences in outcomes into account. Methods: A cost-effectiveness analysis with a 3-year time horizon was performed to simulate the economic consequences of either treatment from the perspective of a third party payer in the United States. We extrapolated results from the comparator trial and used data regarding clinical outcomes, quality of life, and costs from published literature and proprietary databases. A Markov structure was used to consider transitions between health states, defined principally by levels of percent predicted of FEV1. Extensive scenario and probabilistic sensitivity analyses were performed. Measurements and Main Results: Use of aztreonam lysine for inhalation was associated with an average cost saving of $41,947 per patient over 3 years, as well as greater quality-adjusted life-years and total life-years. Scenario analyses demonstrated that these findings were robust to changes in key assumptions. Conclusions: It appears, with high likelihood, that the use of aztreonam solution for inhalation is associated with cost savings, an increase in quality-adjusted life-years, and improved clinical outcomes among patients with extensive prior use of tobramycin solution for inhalation who are naive to inhaled aztreonam lysine.",
keywords = "Aztreonam lysine for inhalation, Cost analysis, Cystic fibrosis, Economic evaluation, Tobramycin solution for inhalation",
author = "Schechter, {Michael S.} and David Trueman and Rachel Farquharson and Keiko Higuchi and Daines, {Cori L}",
year = "2015",
month = "7",
day = "1",
doi = "10.1513/AnnalsATS.201312-453OC",
language = "English (US)",
volume = "12",
pages = "1030--1038",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "7",

}

TY - JOUR

T1 - Inhaled aztreonam lysine versus inhaled tobramycin in cystic fibrosis an economic evaluation

AU - Schechter, Michael S.

AU - Trueman, David

AU - Farquharson, Rachel

AU - Higuchi, Keiko

AU - Daines, Cori L

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Rationale: Pseudomonas aeruginosa infection is a significant cause of morbidity and mortality in patients with cystic fibrosis and is associated with a high economic burden. A recently published comparator trial demonstrated that outcomes in patients with cystic fibrosis with chronic P. aeruginosa infections switched from tobramycin solution for inhalation to aztreonam lysine for inhalation were better than those of patients who continued on tobramycin. Objectives: To compare overall costs of treatment of chronic inhaled tobramycin and aztreonam lysine in patient with cystic fibrosis who have chronic Pseudomonas infection, taking differences in outcomes into account. Methods: A cost-effectiveness analysis with a 3-year time horizon was performed to simulate the economic consequences of either treatment from the perspective of a third party payer in the United States. We extrapolated results from the comparator trial and used data regarding clinical outcomes, quality of life, and costs from published literature and proprietary databases. A Markov structure was used to consider transitions between health states, defined principally by levels of percent predicted of FEV1. Extensive scenario and probabilistic sensitivity analyses were performed. Measurements and Main Results: Use of aztreonam lysine for inhalation was associated with an average cost saving of $41,947 per patient over 3 years, as well as greater quality-adjusted life-years and total life-years. Scenario analyses demonstrated that these findings were robust to changes in key assumptions. Conclusions: It appears, with high likelihood, that the use of aztreonam solution for inhalation is associated with cost savings, an increase in quality-adjusted life-years, and improved clinical outcomes among patients with extensive prior use of tobramycin solution for inhalation who are naive to inhaled aztreonam lysine.

AB - Rationale: Pseudomonas aeruginosa infection is a significant cause of morbidity and mortality in patients with cystic fibrosis and is associated with a high economic burden. A recently published comparator trial demonstrated that outcomes in patients with cystic fibrosis with chronic P. aeruginosa infections switched from tobramycin solution for inhalation to aztreonam lysine for inhalation were better than those of patients who continued on tobramycin. Objectives: To compare overall costs of treatment of chronic inhaled tobramycin and aztreonam lysine in patient with cystic fibrosis who have chronic Pseudomonas infection, taking differences in outcomes into account. Methods: A cost-effectiveness analysis with a 3-year time horizon was performed to simulate the economic consequences of either treatment from the perspective of a third party payer in the United States. We extrapolated results from the comparator trial and used data regarding clinical outcomes, quality of life, and costs from published literature and proprietary databases. A Markov structure was used to consider transitions between health states, defined principally by levels of percent predicted of FEV1. Extensive scenario and probabilistic sensitivity analyses were performed. Measurements and Main Results: Use of aztreonam lysine for inhalation was associated with an average cost saving of $41,947 per patient over 3 years, as well as greater quality-adjusted life-years and total life-years. Scenario analyses demonstrated that these findings were robust to changes in key assumptions. Conclusions: It appears, with high likelihood, that the use of aztreonam solution for inhalation is associated with cost savings, an increase in quality-adjusted life-years, and improved clinical outcomes among patients with extensive prior use of tobramycin solution for inhalation who are naive to inhaled aztreonam lysine.

KW - Aztreonam lysine for inhalation

KW - Cost analysis

KW - Cystic fibrosis

KW - Economic evaluation

KW - Tobramycin solution for inhalation

UR - http://www.scopus.com/inward/record.url?scp=84942238755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942238755&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201312-453OC

DO - 10.1513/AnnalsATS.201312-453OC

M3 - Article

VL - 12

SP - 1030

EP - 1038

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 7

ER -